ArticleFrontiers in immunology2025
High-level ePVS was accompanied by an increase in kidney transplant failure risk: analysis based on the MIMIC-IV database.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of kidney transplantation is currently assessed primarily through clinical monitoring, which involves considerable time and financial costs. Estimated plasma volume status (ePVS) has emerged as a straightforward and efficient method for evaluating patient condition. However, the potential prognostic significance of ePVS in kidney transplant recipients has yet to be thoroughly investigated. Methods: The clinical data for the patient were obtained from the MIMIC-IV database. ePVS was calculated based on hematocrit and hemoglobin values upon admission. Baseline characteristics were compared according to ePVS quartiles, and the relationship between ePVS levels and kidney transplant failure (KTF) in patients was assessed using a Logistic regression model. Results: 4,421 eligible subjects (2,584 males and 1,837 females) with an average age of 52.53 ± 13.00 years old were included in our study. 3,661 (82.80%) had no kidney transplant failure (No-KTF) and 760 (17.20%) had kidney transplant failure (KTF). The ePVS values exhibited a skewed distribution, with the admission patients concentrated in the range of 4-8 mL/g and the discharge patients concentrated in the range of 6-10 mL/g. The ePVS level in the KTF group (7.20 [5.78, 8.85]) was significantly higher than that in the non-KTF group (6.12 [4.95, 7.60]) ( Conclusion: In this study, we found that higher ePVS values were accompanied by an increase in KTF risk, and this association proved robust and independent of age, gender, and comorbidities. Additionally, in our subgroup analysis, including interactive validation, we found that regardless of admission or discharge, the risk of KTF was greater when ePVS increased in non-heart failure. Therefore, ePVS may be an important reference parameter for kidney transplant patients and help improve risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.